Foamix于2003年1月19号在以色列成立。该公司是一家临床阶段制药公司专注于开发和商业化公司专有的泡沫米诺环素治疗痤疮,脓疱疮等皮肤状况。该公司的主导候选产品,fmx101为中度至重...查看全文
牛唐2018-07-28 22:07
$Foamix(FOMX)$ FMX101是外用的minocyline,用于治疗痤疮,预计今年下半年或明年上半年申报NDA,如果获批的话,将是首个获批的米诺环素外用药查看全文
$Foamix(FOMX)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-000600 Act: 33 Size: 1 KB 网页链接
$Foamix(FOMX)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001104659-20-035792 Act: 34 Size: 10 KB 网页链接
$Foamix(FOMX)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001104659-20-035405 Act: 33 Size: 38 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035407 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035409 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035410 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001104659-20-035413 Act: 33 Size: 37 KB 网页链接
$Foamix(FOMX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-019905 Size: 19 KB 网页链接
$Foamix(FOMX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001178913-20-000792 Act: 34 Size: 8 MB 网页链接
$Foamix(FOMX)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001178913-20-000788 Act: 34 Size: 296 KB 网页链接